Globotriaosylceramide (Gb3) (Gb3)

Globotriaosylceramide (Gb3), also known as ceramide trihexoside or CD77, is a neutral glycosphingolipid consisting of a ceramide backbone and a trisaccharide headgroup (PubChem CID 11231). It is a key component of mammalian cell membranes, particularly within lipid rafts, where it facilitates signal transduction and maintains membrane integrity (PubMed: 20538606). In healthy cells, Gb3 is synthesized from lactosylceramide and subsequently degraded in lysosomes by the enzyme alpha-galactosidase A. A deficiency in this enzyme leads to Fabry disease, characterized by the systemic accumulation of Gb3 in tissues such as the heart, kidneys, and vascular endothelium, leading to progressive organ damage (NIH: Fabry Disease). Beyond its role in metabolic disease, Gb3 serves as the essential host cell receptor for Shiga toxins produced by certain bacteria, facilitating toxin internalization and subsequent inhibition of protein synthesis (Sandvig et al., 2010). Therapeutic interventions targeting Gb3 include enzyme replacement therapies like agalsidase beta, which degrade the lipid, and substrate reduction therapies like venglustat, which inhibit its synthesis by targeting upstream enzymes (Marshall et al., 2019).

Other names

Ceramide trihexosideCTHCD77Pk blood group antigenGal-Gal-Glc-CerGlobotriaosylceramide

Drugs targeting globotriaosylceramide primarily work through three mechanisms: enzyme replacement therapy (ERT) which provides exogenous alpha-galactosidase A to degrade the substrate; pharmacological chaperones which stabilize endogenous mutant enzymes to improve degradation; and substrate reduction therapy (SRT) which inhibits upstream enzymes like glucosylceramide synthase to decrease the production of Gb3 precursors.